Could a single injection tame the immune system in lupus?

NCT ID NCT07749651

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This early-stage trial is testing a single injection of an experimental drug called SHR-7012 in healthy adults. The main goal is to check how safe and tolerable the drug is, and how the body absorbs and processes it. The study involves about 50 participants aged 18 to 55, who will receive either the drug or a placebo. While this trial does not include people with the disease, the drug is being developed as a potential future treatment for cutaneous lupus erythematosus, a skin condition linked to an overactive immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SHR-7012 injection
What this could lead to
If successful, this could pave the way for a new treatment option for cutaneous lupus erythematosus, a skin condition caused by an overactive immune system.
What could go wrong
This is an early-stage trial in healthy volunteers, so it won't show whether the drug works for the disease. The drug may cause side effects or fail to show promise in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, 314408, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.